Purification of antigenic peptide from murine hepatoma cells recognized by Class-I major histocompatibility complex molecule-restricted cytotoxic T- lymphocytes induced with B7-1-gene-transfected hepatoma cells

Journal of Hepatology

Volumn 30, Issue 6, 1999, Pages 1119-1129

  Nakatsuka, Katsuhisa ^a   Sugiyama, Hirotaka ^a   Nakagawa, Yohko ^a   Takahashi, Hidemi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Class I MHC molecules; Costimulatory molecules; CTLs; Epitope; Hepatocellular carcinoma

Indexed keywords

B7 ANTIGEN; CHROMIUM 51; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CELL ACTIVATION; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HEPATOMA CELL; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; T LYMPHOCYTE;

EID: 0033068026     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80268-2     Document Type: Article

References (53)

1. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 33:1976;241-259.
2. Hellström KE, Hellström I. Principles of tumor immunity: tumor antigens. DeVita VT Jr., Hellman S, Rosenberg SA, . The Biologic Therapy of Cancer. 1991;35-52 J.B. Lippincott Company, Philadelphia.
3. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 49:1991;281-355.
4. Björkman PJ, Saper MA, Samraoui B, Bennet WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 329:1987;512-518.
5. Ioachim HL. The opportunistic tumors of immune deficiency. Adv Cancer Res. 54:1990;301-317.
6. Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity. J Exp Med. 151:1980;69-80.
7. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med. 2:1996;1361-1366.
8. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back. J Immunol. 158:1997;4521-4524.
9. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytotoxic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 138:1987;989-995.
10. Osband ME, Ross S. Problems in the investigational study and clinical use of cancer immunotherapy. Immunol Today. 11:1990;193-195.
11. Elliot BE, Carlow DA, Rodricks AM, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res. 53:1989;181-244.
12. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 11:1990;237-244.
13. Jewett A, Bonavida B. Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol. 156:1996;907-915.
14. Lann-Terrisse ADL, Fournie GJ, Benoist H. nucleosome-dependent escape of tumor cells from natural-killer-mediated lysis: nucleosomes are taken up by target cells and act at a postconjugation level. Cancer Immunol Immunother. 43:1997;337-344.
15. Tanaka K, Isselbacher KJ, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science. 228:1985;26-30.
16. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transformation. Nature. 311:1984;750-752.
17. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 7:1989;445-480.
18. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplasmic B Cells. J Immunol. 143:1989;2714-2722.
19. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and Interleukin 2 mRNA accumulation. J Exp Med. 173:1991;721-730.
20. Galvin F, Freeman GJ, Razi-Wolf Z, Hall W, Benacerraf B, Nadler L, et al. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J Immunol. 149:1992;3802-3808.
21. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 366:1993;76-79.
22. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 262:1993;909-911.
23. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB1. Proc Natl Acad Sci USA. 87:1990;5031-5035.
24. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 174:1991;561-569.
25. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, et al. Long term survival of xenogenic pancreatic islets induced by CTLA4Ig. Science. 257:1992;789-792.
26. + T cells by B7-transfected melanoma cells. Science. 259:1993;368-370.
27. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, et al. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecule CD28 and CTLA-4. Cell. 71:1992;1093-1102.
28. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med. 179:1994;1205-1214.
29. Gajewski TF, Renauld JC, Pel AV, Boon T. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytotoxic T lymphocytes in vitro. J Immunol. 154:1995;5637-5648.
30. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55:1995;3598-3603.
31. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvill SS, Sobel RA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
32. Townsend A, Claes Ö, Bastin J, Ljunggeren HG, Foster L, Kärre K. Association of class-I major histocompatibility heavy and light chains induced by viral peptides. Nature. 340:1989;443-448.
33. Takahashi H, Cease KB, Berzofsky JA. Identification of proteases that process distinct epitopes on the same protein. J Immunol. 142:1989;2221-2229.
34. Tsukui T, Kikuchi K, Mabuchi A, Sudo T, Sakamoto T, Sato N, et al. Production of macrophage colony-stimulating factor by adult murine parenchemal liver cells (hepatocytes). J Leucoc Biol. 52:1992;383-389.
35. Ceredig R, Lowenthal JW, Nabholz M, MacDonald HR. Expression of Interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature. 314:1985;98-100.
36. Sarmiento M, Glaseblook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol. 125:1980;2665-2672.
37. Ozato K, Sachs DH. Monoclonal antibodies to mouse MHC antigens. J Immunol. 126:1981;317-321.
38. Liu Y, Jones B, Aruffo A, Sullivan KM, Linsley PS, Janeway CA. Heat stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med. 175:1992;437-445.
39. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette J, et al. An immunodominat epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T-lymphocytes. Proc Natl Acad Sci USA. 85:1988;3105-3109.
40. Storkus WJ, Zeh III HJ, Salter RD, Lotze MT. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother. 14:1993;94-103.
41. Sabzevari H, Reisfeld RA. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice. Cancer Res. 53:1993;4933-4937.
42. b-restricted CTL despite decreased MHC class I antigen expression. Cell Immunol. 136:1991;414-424.
43. Tatsumi T, Takehara T, Katayama K, Mochizuki K, Yamamoto M, Kanto T, et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology. 25:1997;1108-1114.
44. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, et al. Tumor immunogeneicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 179:1994;523-532.
45. Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity. 5:1996;311-317.
46. Lacabanne V, Viguier M, Guillet JG, Choppin J. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol. 26:1996;2635-2639.
47. Rosenberg SA. Cancer vaccines based on the idetification of genes encoding cancer regression antigens. Immunol Today. 18:1997;175-182.
48. Pardoll D. Maturation of cancer vaccines. A meeting report on"Cancer Vaccines 1996" sponsored by the Cancer Research Institute, held October 7-9, 1996. Biochim Biophys Acta. 1332:1997;R33-R36.
49. Ertl HCJ, Xiang Z. Novel vaccine approaches. J Immunol. 156:1996;3579-3582.
50. Melief CJ, Offringa R, Toes RE, Kast WM. Peptide-based cancer vaccines Curr Opin Immunology. 8:1996;651-657.
51. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-I. J Immunol. 154:1995;2257-2265.
52. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 183:1996;87-97.
53. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-I envelope derived peptide-pulsed dendritic cells. Int Immunol. 5:1993;849-857.